RTP Mobile Logo
Data and Perspectives: Clinical Investigators Review Key Publications and Current Cases in Multiple Myeloma and Non-Hodgkin Lymphoma
Released September 2014

Proceedings from a CME symposium held at the 2014 ASCO Annual Meeting. Featuring perspectives from Drs Jonathan W Friedberg, Sagar Lonial, Martin Dreyling, Michelle A Fanale, Kenneth C Anderson and Michael E Williams. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for hematologists, medical oncologists and other allied healthcare professionals involved in the treatment of hematologic cancers.

    OVERVIEW OF ACTIVITY
    One would be hard pressed to find another area of medical oncology in which the research database is evolving as rapidly as it is in multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). Taken together, it is estimated that approximately 156,420 new lymphoid and myeloid cancer cases will be identified in the United States in the year 2014, and 55,350 individuals will die from these diseases. Recent advances have led to an explosion of genetic and biologic knowledge among scientists and clinicians working in this area, culminating in more than 60 drug products labeled for use in the management of hematologic cancers with more than 70 distinct FDA-approved indications.

    By providing access to the latest research developments and expert perspectives, these proceedings from a case-based CME symposium held at the 2014 ASCO Annual Meeting aim to assist hematologists, medical oncologists and other healthcare providers who must maintain up-to-date knowledge of appropriate clinical management strategies and ongoing research in these 2 distinct yet related diseases.

    LEARNING OBJECTIVES

    • Compare and contrast completed and ongoing clinical trials evaluating novel investigational approaches for B-cell lymphomas and chronic lymphocytic leukemia (CLL), and prioritize clinical trial opportunities or expanded-access programs available to patients based on this information.
    • Appreciate the recent FDA approvals of ibrutinib and obinutuzumab, and discern how these agents can be appropriately integrated into clinical practice for patients with CLL.
    • Customize the selection of systemic therapy for patients with progressive mantle-cell lymphoma, recognizing the recent addition of new FDA-endorsed options for these patients.
    • Recognize the role of novel agents in the management of peripheral T-cell lymphoma and/or advanced-stage T-cell lymphomas, and ensure appropriate supportive care measures to minimize side effects.
    • Compare and contrast the benefits and risks of available immunomodulatory agents, proteasome inhibitors or both as systemic treatment for newly diagnosed active MM.
    • Customize the use of maintenance therapeutic approaches in the post-transplant and nontransplant settings based on patient- and disease-related factors, including cytogenetic profile.
    • Consider available data on the selection, sequencing and/or combination of carfilzomib and pomalidomide in the management of relapsed/refractory MM.
    • Assess the ongoing clinical trials evaluating innovative investigational approaches for NHL and MM, and refer appropriate patients for study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. The participant should watch the video and complete the Post-test.


    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Jonathan W Friedberg, MD, MMSc
    Samuel Durand Professor of Medicine
    Director, Wilmot Cancer Center
    University of Rochester
    Rochester, New York

    Advisory Committee and Other Uncompensated Activities: Genentech BioOncology.

    Sagar Lonial, MD
    Professor
    Vice Chair of Clinical Affairs
    Director of Translational Research
    B-Cell Malignancy Program
    Department of Hematology and Medical Oncology
    Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, Georgia

    Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Sanofi.

    Martin Dreyling, MD, PhD
    Professor of Medicine
    Department of Medicine III
    University Hospital LMU Munich
    Munich, Germany

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Janssen Pharmaceuticals Inc, Pfizer Inc; Contracted Research: Celgene Corporation, Janssen Pharmaceuticals Inc, Mundipharma International Limited, Pfizer Inc, Roche Laboratories Inc; Speaking Honoraria: Celgene Corporation, Janssen Pharmaceuticals Inc, Pfizer Inc.

    Michelle A Fanale, MD
    Associate Professor
    Department of Lymphoma and Myeloma at
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Amgen Inc, Seattle Genetics, Spectrum Pharmaceuticals Inc; Consulting Agreement: Seattle Genetics; Contracted Research: Celgene Corporation, Genentech BioOncology, MedImmune Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Seattle Genetics.

    Kenneth C Anderson, MD
    Kraft Family Professor of Medicine
    Harvard Medical School
    Director, Jerome Lipper Multiple Myeloma Center
    Director, LeBow Institute for Myeloma Therapeutics
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Sanofi.

    Michael E Williams, MD, ScM
    Byrd S Leavell Professor of Medicine
    Chief, Hematology/Oncology Division
    University of Virginia School of Medicine
    Charlottesville, Virginia

    Advisory Committee: Celgene Corporation, Genentech BioOncology, Onyx Pharmaceuticals Inc; Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company; Contracted Research: Allos Therapeutics, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pharmacyclics Inc.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc and Spectrum Pharmaceuticals Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: September 2014
    Expiration date: September 2015

Acknowledge and close

View video: